These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

878 related items for PubMed ID: 29039054

  • 1. Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA.
    Chastek B, Chen CI, Proudfoot C, Shinde S, Kuznik A, Wei W.
    Adv Ther; 2017 Nov; 34(11):2422-2435. PubMed ID: 29039054
    [Abstract] [Full Text] [Related]

  • 2. Outcomes of tumor necrosis factor inhibitor cycling versus switching to a disease-modifying anti-rheumatic drug with a new mechanism of action among patients with rheumatoid arthritis.
    Chastek B, Becker LK, Chen CI, Mahajan P, Curtis JR.
    J Med Econ; 2017 May; 20(5):464-473. PubMed ID: 28010149
    [Abstract] [Full Text] [Related]

  • 3. Treatment Persistence and Clinical Outcomes of Tumor Necrosis Factor Inhibitor Cycling or Switching to a New Mechanism of Action Therapy: Real-world Observational Study of Rheumatoid Arthritis Patients in the United States with Prior Tumor Necrosis Factor Inhibitor Therapy.
    Wei W, Knapp K, Wang L, Chen CI, Craig GL, Ferguson K, Schwartzman S.
    Adv Ther; 2017 Aug; 34(8):1936-1952. PubMed ID: 28674959
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators.
    Jansen JP, Incerti D, Mutebi A, Peneva D, MacEwan JP, Stolshek B, Kaur P, Gharaibeh M, Strand V.
    J Med Econ; 2017 Jul; 20(7):703-714. PubMed ID: 28294642
    [Abstract] [Full Text] [Related]

  • 5. Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study.
    Wu N, Lee YC, Shah N, Harrison DJ.
    Clin Ther; 2014 Aug 01; 36(8):1231-41, 1241.e1-3. PubMed ID: 25062652
    [Abstract] [Full Text] [Related]

  • 6. Healthcare-Related Costs Associated with Switching Subcutaneous Tumor Necrosis Factor-α Inhibitor in the Treatment of Inflammatory Arthritis: a Retrospective Study.
    Dalén J, Luttropp K, Svedbom A, Black CM, Kachroo S.
    Adv Ther; 2020 Sep 01; 37(9):3746-3760. PubMed ID: 32647910
    [Abstract] [Full Text] [Related]

  • 7. Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study.
    Pappas DA, St John G, Etzel CJ, Fiore S, Blachley T, Kimura T, Punekar R, Emeanuru K, Choi J, Boklage S, Kremer JM.
    Ann Rheum Dis; 2021 Jan 01; 80(1):96-102. PubMed ID: 32719038
    [Abstract] [Full Text] [Related]

  • 8. Economic Burden of Switching to a Non-Tumor Necrosis Factor Inhibitor Versus a Tumor Necrosis Factor Inhibitor Biologic Therapy among Patients with Rheumatoid Arthritis.
    Zhou ZY, Griffith J, Du EX, Chin D, Betts KA, Ganguli A.
    Adv Ther; 2016 May 01; 33(5):807-23. PubMed ID: 27084724
    [Abstract] [Full Text] [Related]

  • 9. Economic Evaluation of Sarilumab in the Treatment of Adult Patients with Moderately-to-Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs.
    Muszbek N, Proudfoot C, Fournier M, Chen CI, Kuznik A, Kiss Z, Gal P, Michaud K.
    Adv Ther; 2019 Jun 01; 36(6):1337-1357. PubMed ID: 31004324
    [Abstract] [Full Text] [Related]

  • 10. Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis After a Change in Targeted Therapy.
    Bonafede MMK, McMorrow D, Proudfoot C, Shinde S, Kuznik A, Chen CI.
    Am Health Drug Benefits; 2018 Jun 01; 11(4):192-202. PubMed ID: 30464787
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of Real-World Experience with Tofacitinib Compared with Adalimumab, Etanercept, and Abatacept in RA Patients with 1 Previous Biologic DMARD: Data from a U.S. Administrative Claims Database.
    Harnett J, Gerber R, Gruben D, Koenig AS, Chen C.
    J Manag Care Spec Pharm; 2016 Dec 01; 22(12):1457-1471. PubMed ID: 27882833
    [Abstract] [Full Text] [Related]

  • 12. An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis After Methotrexate or After 1 or 2 TNF Inhibitors from a U.S. Payer Perspective.
    Claxton L, Taylor M, Soonasra A, Bourret JA, Gerber RA.
    J Manag Care Spec Pharm; 2018 Oct 01; 24(10):1010-1017. PubMed ID: 29897007
    [Abstract] [Full Text] [Related]

  • 13. The economic burden of switching targeted disease-modifying anti-rheumatic drugs among rheumatoid arthritis patients.
    Shahabi A, Shafrin J, Zhao L, Green S, Curtice T, Marshall A, Paul D.
    J Med Econ; 2019 Apr 01; 22(4):350-358. PubMed ID: 30653389
    [Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness of TNF inhibitors vs synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a Markov model study based on two longitudinal observational studies.
    Kvamme MK, Lie E, Uhlig T, Moger TA, Kvien TK, Kristiansen IS.
    Rheumatology (Oxford); 2015 Jul 01; 54(7):1226-35. PubMed ID: 25573840
    [Abstract] [Full Text] [Related]

  • 15. Comparison of the clinical effectiveness of tumour necrosis factor inhibitors and abatacept after insufficient response to tocilizumab in patients with rheumatoid arthritis.
    Akiyama M, Kaneko Y, Kondo H, Takeuchi T.
    Clin Rheumatol; 2016 Nov 01; 35(11):2829-2834. PubMed ID: 26971256
    [Abstract] [Full Text] [Related]

  • 16. Clinical Outcomes and Biologic Costs of Switching Between Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis.
    Cannon GW, DuVall SL, Haroldsen CL, Caplan L, Curtis JR, Michaud K, Mikuls TR, Reimold A, Collier DH, Joseph GJ, Harrison DJ, Sauer BC.
    Adv Ther; 2016 Aug 01; 33(8):1347-59. PubMed ID: 27352377
    [Abstract] [Full Text] [Related]

  • 17. Tocilizumab after a first-line with anti-TNF in rheumatoid arthritis: a cost-consequence analysis in the Italian setting.
    Iannazzo S, Benucci M, Favalli EG.
    Clin Exp Rheumatol; 2018 Aug 01; 36(3):479-485. PubMed ID: 29352843
    [Abstract] [Full Text] [Related]

  • 18. Cost per patient-year in response using a claims-based algorithm for the 2 years following biologic initiation in patients with rheumatoid arthritis.
    Bonafede M, Johnson BH, Princic N, Shah N, Harrison DJ.
    J Med Econ; 2015 May 01; 18(5):376-89. PubMed ID: 25530318
    [Abstract] [Full Text] [Related]

  • 19. Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases.
    Silvagni E, Bortoluzzi A, Carrara G, Zanetti A, Govoni M, Scirè CA.
    BMJ Open; 2018 Sep 11; 8(9):e021447. PubMed ID: 30206082
    [Abstract] [Full Text] [Related]

  • 20. Treatment persistence among patients with immune-mediated rheumatic disease newly treated with subcutaneous TNF-alpha inhibitors and costs associated with non-persistence.
    Dalén J, Svedbom A, Black CM, Lyu R, Ding Q, Sajjan S, Sazonov V, Kachroo S.
    Rheumatol Int; 2016 Jul 11; 36(7):987-95. PubMed ID: 26780533
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.